TARPON SPRINGS, Fla., June 30, 2026
Allarity Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted a key U.S. patent covering its proprietary Drug Response Predictor (DRP®) companion diagnostic for stenoparib, providing intellectual property protection through April 2042. The newly issued patent secures exclusive rights for the combined use of stenoparib and the stenoparib-DRP® companion diagnostic in the United States, strengthening the company’s long-term precision medicine technology strategy. The patent follows the Notice of Allowance received in April 2026 and establishes a strong intellectual property foundation for Allarity’s gene-expression-based patient selection platform. According to the company, the technology is designed to identify patients most likely to benefit from stenoparib treatment, supporting a more personalized approach to cancer therapy while advancing the investigational treatment toward potential regulatory approval.
Patent Protects Proprietary Companion Diagnostic Technology
The newly granted patent covers methods for predicting clinical response to stenoparib using gene-expression profiles generated from patient tumor samples. It also protects methods for selecting patients with the highest likelihood of benefiting from therapy through the proprietary stenoparib DRP® companion diagnostic. By safeguarding both the predictive biomarker technology and the patient selection methodology, the patent provides Allarity with long-term exclusivity for integrating the companion diagnostic with stenoparib until 2042. The company has also secured corresponding patent protection in Europe and Australia through 2039, while additional applications remain under review in several international markets, expanding the global intellectual property portfolio supporting its precision oncology platform.
DRP® Platform Advances Precision Medicine Through Gene Expression Analysis
Allarity’s Drug Response Predictor (DRP®) platform is designed to improve cancer treatment by using messenger RNA (mRNA) gene-expression signatures to identify patients who are most likely to respond to specific therapies before treatment begins. The platform combines transcriptomic analysis, drug sensitivity data from human cancer cell lines, clinical tumor biology, and historical clinical trial outcomes to generate individualized treatment predictions. By selecting patients with a high probability of response, the technology aims to improve treatment outcomes while reducing unnecessary exposure to therapies unlikely to provide clinical benefit. According to the company, the DRP® platform has demonstrated statistically significant predictive performance across numerous retrospective and prospective oncology studies involving multiple anti-cancer drugs, supporting its broader application across precision medicine.
Advertisement
Technology Supports Future Development of Personalized Cancer Therapies
The patented DRP® companion diagnostic forms a central component of Allarity’s strategy to integrate diagnostic technology with targeted cancer therapies. The company’s lead investigational therapy, stenoparib (2X-121), is a dual PARP1/2 and tankyrase 1/2 inhibitor currently being evaluated in Phase 2 clinical studies for advanced ovarian cancer, with additional development programs in small cell lung cancer and colorectal cancer. By pairing innovative therapeutics with predictive diagnostic tools, Allarity aims to deliver a more personalized treatment approach that improves patient selection and enhances clinical outcomes. The newly granted U.S. patent significantly strengthens the company’s .Tech portfolio by protecting its proprietary biomarker-driven platform and reinforcing its position in the rapidly expanding field of precision oncology and companion diagnostic technologies.
Source: Allarity Therapeutics press release
